联合健康(UNH.N)盘前跌幅达8%。 ...

联合健康(UNH.N)：许多新的医疗保险优势受益人的医疗费用仍然高于预期。 ...

联合健康(UNH.N)：暂停2025年展望。预计医疗支出将高于预期。 ...

联合健康暂停对2025年的展望，预计将在2026年恢复增长。 ...

联合健康(UNH.N)：预计将在2026年实现增长。 ...

Core Viewpoint - A class action lawsuit has been filed against UnitedHealth Group Incorporated, alleging securities fraud and unlawful business practices [2][3]. Financial Performance - On April 17, 2025, UnitedHealth reported its Q1 2025 financial results and revised its full-year guidance, lowering its net earnings outlook to a range of $24.65 to $25.15 per share from a previous range of $28.15 to $28.65 per share [3]. - The adjusted earnings outlook was also revised down to a range of $26.00 to $26.50 per share, compared to the earlier guidance of $29.50 to $30.00 per share [3]. - The company indicated that the revised outlook was due to heightened care activity for Medicare Advantage beneficiaries, which exceeded planned increases [3]. Stock Market Reaction - Following the announcement of the revised guidance, UnitedHealth's stock price fell by $159.71 per share, or 27%, closing at $425.33 per share on April 18, 2025 [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against UnitedHealth Group Incorporated, alleging misrepresentations regarding the company's ability to meet its earnings guidance [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired UnitedHealth securities between December 3, 2024, and April 16, 2025 [1]. - Defendants are accused of making false statements about the company's capacity to achieve its net and adjusted earnings per share guidance [2]. Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file papers by July 7, 2025 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [3]. Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions [4].

Core Viewpoint - A class action lawsuit has been filed against UnitedHealth Group Incorporated for alleged violations of federal securities laws during the class period from December 3, 2024, to April 16, 2025 [2][3] Group 1: Allegations Against UnitedHealth - The lawsuit claims that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3] - It is alleged that this strategy led to regulatory scrutiny and public outrage, culminating in the murder of an individual named Brian Thompson [3] - Following the murder, there was significant public animosity towards UnitedHealth, with some individuals expressing admiration for the accused killer [3] - The company reportedly changed its corporate practices in response to the regulatory and public backlash [3] - Despite these changes, UnitedHealth continued to issue guidance that was deemed unrealistic given the evolving corporate strategies [3] Group 2: Legal Process and Participation - Investors who suffered losses in UnitedHealth have until July 7, 2025, to request to be appointed as lead plaintiff in the class action [4] - Participation in any recovery does not require serving as lead plaintiff [4] - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5] Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6]

Core Viewpoint - A class action lawsuit has been filed against UnitedHealth Group Incorporated, alleging securities fraud and unlawful business practices [2][4]. Group 1: Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline of July 7, 2025, to apply as Lead Plaintiff [2][3]. - The lawsuit pertains to potential misconduct by UnitedHealth and its officers or directors [2]. Group 2: Financial Performance and Market Reaction - On April 17, 2025, UnitedHealth revised its 2025 net earnings outlook to a range of $24.65 to $25.15 per share, down from a previous guidance of $28.15 to $28.65 per share [4]. - The adjusted earnings outlook was also revised to a range of $26.00 to $26.50 per share, compared to the earlier guidance of $29.50 to $30.00 per share [4]. - Following the announcement, UnitedHealth's stock price dropped by $159.71 per share, or 27%, closing at $425.33 per share on April 18, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against UnitedHealth Group Inc. after a significant drop in its market capitalization, amounting to approximately $170 billion, following disappointing Q1 2025 financial results and a reduction in FY 2025 guidance [1][3]. Group 1: Lawsuit Details - The lawsuit, Faller v. UnitedHealth Group Inc., seeks to represent investors who purchased UnitedHealth securities between December 3, 2024, and April 16, 2025 [1][2]. - The lawsuit challenges UnitedHealth's guidance for FY 2025 net EPS, which was initially set at $28.15 to $28.65 and adjusted EPS of $29.50 to $30.00, later revised down to net EPS of $24.65 to $25.15 and adjusted EPS of $26.00 to $26.50 [3][4]. - Allegations include that UnitedHealth made false and misleading statements while failing to disclose critical information regarding its business practices, particularly in its Medicare Advantage segment [2][3]. Group 2: Market Reaction - Following the announcement of the revised guidance on April 17, 2025, UnitedHealth's share price plummeted by 22% [4]. - Analysts have suggested that the company's potential changes in corporate strategies regarding utilization management may have contributed to the drastic revision of guidance [4]. Group 3: Corporate Strategy and Public Sentiment - UnitedHealth has faced scrutiny for its corporate strategy of denying health coverage to enhance profits, which has led to regulatory and public backlash [5]. - The murder of Brian Thompson, the CEO of UnitedHealthcare, on December 4, 2024, intensified public animosity towards the company, with many Americans expressing negative sentiments towards UnitedHealth [5]. - Despite the public outrage and changes in corporate practices, UnitedHealth continued to issue guidance that was deemed unrealistic given the evolving corporate strategies [5].